Inhibition by aspirin of N-[4-(5-nitro-2furyl)-2thiazolyl]formamide induced bladder carcinogenesis and enhancement of forestomach carcinogenesis

G. Murasaki, T. V. Zenser, B. B. Davis, Samuel Monroe Cohen

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide (FANFT) is a potent urinary bladder carcinogen in the rat, and it can be metabolically activated in vitro by a variety of enzyme systems including aerobic cooxidation by prostaglandin H synthase. The latter enzyme is present in the rat bladder mucosa and can be inhibited by the oral administration of aspirin (ASA). To determine if ASA could inhibit the bladder carrinogenidty of FANFT, FANFT (0.2%) was co-administered in the diet with ASA (0.5%) for 12 weeks followed by 1 week of ASA only and then 56 weeks on control diet. 0.2% FANFT followed by control diet induced bladder carcinomas in 18 of 21 (87%) rats, but when ASA was co-administered, only 10 of 27 (37%) rats dweloped bladder cardnoma (p <0.001). However, forestomach tumors, not seen in rats fed only FANFT, developed in 7 rats fed FANFT plus ASA. No tumors occurred in control rats or those fed only ASA. Possible mechanisms, including the role of prostaglandin H synthase in FANFT metabolism, are discussed.

Original languageEnglish (US)
Pages (from-to)53-55
Number of pages3
JournalCarcinogenesis
Volume5
Issue number1
DOIs
StatePublished - Jan 1 1984

Fingerprint

FANFT
Aspirin
Carcinogenesis
Urinary Bladder
Prostaglandin-Endoperoxide Synthases
Diet
Enzymes
formamide
Carcinogens
Oral Administration
Neoplasms
Mucous Membrane
Carcinoma

ASJC Scopus subject areas

  • Cancer Research

Cite this

Inhibition by aspirin of N-[4-(5-nitro-2furyl)-2thiazolyl]formamide induced bladder carcinogenesis and enhancement of forestomach carcinogenesis. / Murasaki, G.; Zenser, T. V.; Davis, B. B.; Cohen, Samuel Monroe.

In: Carcinogenesis, Vol. 5, No. 1, 01.01.1984, p. 53-55.

Research output: Contribution to journalArticle

@article{27f1969dad67463cb5349350e03141e4,
title = "Inhibition by aspirin of N-[4-(5-nitro-2furyl)-2thiazolyl]formamide induced bladder carcinogenesis and enhancement of forestomach carcinogenesis",
abstract = "N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide (FANFT) is a potent urinary bladder carcinogen in the rat, and it can be metabolically activated in vitro by a variety of enzyme systems including aerobic cooxidation by prostaglandin H synthase. The latter enzyme is present in the rat bladder mucosa and can be inhibited by the oral administration of aspirin (ASA). To determine if ASA could inhibit the bladder carrinogenidty of FANFT, FANFT (0.2{\%}) was co-administered in the diet with ASA (0.5{\%}) for 12 weeks followed by 1 week of ASA only and then 56 weeks on control diet. 0.2{\%} FANFT followed by control diet induced bladder carcinomas in 18 of 21 (87{\%}) rats, but when ASA was co-administered, only 10 of 27 (37{\%}) rats dweloped bladder cardnoma (p <0.001). However, forestomach tumors, not seen in rats fed only FANFT, developed in 7 rats fed FANFT plus ASA. No tumors occurred in control rats or those fed only ASA. Possible mechanisms, including the role of prostaglandin H synthase in FANFT metabolism, are discussed.",
author = "G. Murasaki and Zenser, {T. V.} and Davis, {B. B.} and Cohen, {Samuel Monroe}",
year = "1984",
month = "1",
day = "1",
doi = "10.1093/carcin/5.1.53",
language = "English (US)",
volume = "5",
pages = "53--55",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Inhibition by aspirin of N-[4-(5-nitro-2furyl)-2thiazolyl]formamide induced bladder carcinogenesis and enhancement of forestomach carcinogenesis

AU - Murasaki, G.

AU - Zenser, T. V.

AU - Davis, B. B.

AU - Cohen, Samuel Monroe

PY - 1984/1/1

Y1 - 1984/1/1

N2 - N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide (FANFT) is a potent urinary bladder carcinogen in the rat, and it can be metabolically activated in vitro by a variety of enzyme systems including aerobic cooxidation by prostaglandin H synthase. The latter enzyme is present in the rat bladder mucosa and can be inhibited by the oral administration of aspirin (ASA). To determine if ASA could inhibit the bladder carrinogenidty of FANFT, FANFT (0.2%) was co-administered in the diet with ASA (0.5%) for 12 weeks followed by 1 week of ASA only and then 56 weeks on control diet. 0.2% FANFT followed by control diet induced bladder carcinomas in 18 of 21 (87%) rats, but when ASA was co-administered, only 10 of 27 (37%) rats dweloped bladder cardnoma (p <0.001). However, forestomach tumors, not seen in rats fed only FANFT, developed in 7 rats fed FANFT plus ASA. No tumors occurred in control rats or those fed only ASA. Possible mechanisms, including the role of prostaglandin H synthase in FANFT metabolism, are discussed.

AB - N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide (FANFT) is a potent urinary bladder carcinogen in the rat, and it can be metabolically activated in vitro by a variety of enzyme systems including aerobic cooxidation by prostaglandin H synthase. The latter enzyme is present in the rat bladder mucosa and can be inhibited by the oral administration of aspirin (ASA). To determine if ASA could inhibit the bladder carrinogenidty of FANFT, FANFT (0.2%) was co-administered in the diet with ASA (0.5%) for 12 weeks followed by 1 week of ASA only and then 56 weeks on control diet. 0.2% FANFT followed by control diet induced bladder carcinomas in 18 of 21 (87%) rats, but when ASA was co-administered, only 10 of 27 (37%) rats dweloped bladder cardnoma (p <0.001). However, forestomach tumors, not seen in rats fed only FANFT, developed in 7 rats fed FANFT plus ASA. No tumors occurred in control rats or those fed only ASA. Possible mechanisms, including the role of prostaglandin H synthase in FANFT metabolism, are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0021357484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021357484&partnerID=8YFLogxK

U2 - 10.1093/carcin/5.1.53

DO - 10.1093/carcin/5.1.53

M3 - Article

C2 - 6690086

AN - SCOPUS:0021357484

VL - 5

SP - 53

EP - 55

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 1

ER -